Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes
Journal of Internal Medicine · 2025-06 · 297 (6) · 584-607
DOI: 10.1111/joim.20090 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 27.04.2025. Verfasst von David Rizo-Roca und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Integrative Physiology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Insulin Resistance, Metabolomics, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Novo Nordisk Fonden, European Commission.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Cardiometabolic diseases—including Type 2 diabetes and obesity—remain leading causes of global mortality. Recent advancements in metabolomics have facilitated the identification of metabolites that are integral to the development of insulin resistance, a characteristic feature of cardiometabolic disease. Key metabolites, such as branched‐chain amino acids (BCAAs), ceramides, glycine, and glutamine, have emerged as valuable biomarkers for early diagnosis, risk stratification, and potential therapeutic targets. Elevated BCAAs and ceramides are strongly associated with insulin resistance and Type 2 diabetes, whereas glycine exhibits an inverse relationship with insulin resistance, making it a promising therapeutic target. Metabolites involved in energy stress, including ketone bodies, lactate, and nicotinamide adenine dinucleotide (NAD⁺), regulate insulin sensitivity and metabolic health, with ketogenic diets and NAD⁺ precursor supplementation showing potential benefits. Additionally, the novel biomarker N ‐lactoyl‐phenylalanine further underscores the complexity of metabolic regulation and its therapeutic potential. This review underscores the potential of metabolite‐based diagnostics and precision medicine, which could enhance efforts in the prevention, diagnosis, and treatment of cardiometabolic diseases, ultimately improving patient outcomes and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Integrative Physiology, Karolinska Institutet, Stockholm, Sweden.
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Molecular Medicine and Surgery, Integrative Physiology, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Juleen R Zierath
Förderung
- Vetenskapsrådet
- Novo Nordisk Fonden
- European Commission
- Knut och Alice Wallenbergs Stiftelse
Zitieren
APA
Rizo-Roca, D., Henderson, J. D., & Zierath, J. R. (2025). Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes. Journal of Internal Medicine, 297(6), 584-607. https://doi.org/10.1111/joim.20090
Vancouver
Rizo-Roca D, Henderson JD, Zierath JR. Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes. Journal of Internal Medicine. 2025;297(6):584-607. doi:10.1111/joim.20090
BibTeX
@article{RizoRoca2025,
author = {Rizo-Roca, David and Henderson, John D and Zierath, Juleen R},
title = {Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes},
journal = {Journal of Internal Medicine},
year = {2025},
volume = {297},
number = {6},
pages = {584--607},
doi = {10.1111/joim.20090}
}
EUVIMED